HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

PDE-5 inhibitors lower portal and pulmonary pressure in portopulmonary hypertension.

AuthorsP Deibert, H Bremer, M Roessle, A-K Kurz-Schmieg, W Kreisel
JournalThe European respiratory journal (Eur Respir J) Vol. 29 Issue 1 Pg. 220-1 (Jan 2007) ISSN: 0903-1936 [Print] England
PMID17197488 (Publication Type: Case Reports, Comment, Letter)
Chemical References
  • Carbolines
  • Phosphodiesterase Inhibitors
  • Tadalafil
  • 3',5'-Cyclic-GMP Phosphodiesterases
  • Cyclic Nucleotide Phosphodiesterases, Type 5
  • PDE5A protein, human
Topics
  • 3',5'-Cyclic-GMP Phosphodiesterases (antagonists & inhibitors)
  • Carbolines (therapeutic use)
  • Cyclic Nucleotide Phosphodiesterases, Type 5
  • Humans
  • Hypertension, Portal (drug therapy)
  • Hypertension, Pulmonary (drug therapy)
  • Male
  • Middle Aged
  • Phosphodiesterase Inhibitors (therapeutic use)
  • Tadalafil

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: